[HTML][HTML] Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
CE Kyriakopoulos, YH Chen, MA Carducci… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, DH Shevrin…
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.govPurpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the
longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we
present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen
Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature
follow-up and focus on tumor volume.
longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we
present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen
Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature
follow-up and focus on tumor volume.
Abstract
Purpose
Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume.
ncbi.nlm.nih.gov